Maintaining Investments in New Innovation Act
Summary
What This Bill Does
The Maintaining Investments in New Innovation Act changes the Inflation Reduction Act's Medicare drug-price negotiation timing for a narrow category of advanced drug products. Under current section 1192(e), certain qualifying single-source drugs can become eligible for negotiation after a set number of years. This bill inserts a special 11-year period, instead of the ordinary 7-year period, for an advanced drug product. It defines that term by reference to genetically targeted technology that may modulate, suppress, up-regulate, or activate a gene or associated gene product. The practical result is more time before Medicare negotiation can apply to certain gene-targeted therapies, which protects revenue windows for developers but delays negotiation leverage for Medicare.
Who Benefits and How
Biotechnology companies benefit because qualifying genetically targeted drugs get four additional years before Medicare negotiation eligibility. Gene therapy developers benefit from a longer protected revenue window for products using gene-modulation technology. Investors in advanced drug products benefit if delayed negotiation improves expected returns for high-risk research programs. Patients needing genetically targeted therapies may benefit indirectly if the longer revenue window supports continued development.
Who Bears the Burden and How
Centers for Medicare and Medicaid Services drug-pricing staff must apply a new advanced-drug definition when selecting negotiation-eligible drugs. Medicare beneficiaries may face delayed negotiated prices for qualifying advanced drug products. Federal taxpayers bear higher spending risk if Medicare cannot negotiate prices for those products as early. Drug-price negotiation advocates lose leverage over a category of high-cost genetically targeted products.
Key Provisions
- Extends the negotiation-delay period to 11 years for qualifying advanced drug products.
- Defines advanced drug products by reference to genetically targeted technology.
- Limits the special rule to drugs that modulate gene or associated gene-product function.
- Delays Medicare negotiation leverage for covered advanced therapies.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Extends the Medicare drug-price negotiation delay from 7 years to 11 years for advanced drug products using genetically targeted technology.
Key Policy Areas
Health Care, Prescription Drugs, Biotechnology
Primary Purpose
Extends the Medicare drug-price negotiation delay from 7 years to 11 years for advanced drug products using genetically targeted technology.
Policy Domains
Resolution provisions
Identified Gains
- Biotechnology companies
- Gene therapy developers
- Drug product investors
- Patients needing genetically targeted therapies
Identified Costs
- Centers for Medicare and Medicaid Services
- Medicare beneficiaries
- Federal taxpayers
- Drug-price negotiation advocates
Sponsors
Legislative Progress
In CommitteeMr. Davis of North Carolina (for himself, Mr. Joyce of …
Referred to the Committee on Energy and Commerce, and in …
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biotechnology companies, Gene therapy developers
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology